Glycomed Inc. deal

Sankyo will invest $1.5 million in the Alameda, Calif., company and pay a $1 million licensing fee. GLYC, which hasn't disclosed the number of shares or the price per share, has 12.6 million shares outstanding.

Sankyo will receive exclusive marketing rights for GLYC's cell adhesion products in the Far East. GLYC will retain all manufacturing rights and will receive sales royalties. There is an additional $5 million attainable for each compound developed. ...